Because there is clear evidence that the FDA would not have approved a stronger warning to the precautions section of the Fosamax label prior to plaintiff's fracture, plaintiffs' failure-to-warn action is pre-empted.
TORTS — Failure To Warn
In re Fosamax (Alendronate Sodium)
New Jersey Law Journal
July 11, 2013